(0.07%) 5 103.52 points
(0.25%) 38 336 points
(0.05%) 15 936 points
(-1.34%) $82.73
(6.34%) $2.05
(0.05%) $2 348.30
(-0.23%) $27.47
(3.83%) $957.45
(-0.19%) $0.933
(-0.29%) $10.99
(-0.52%) $0.796
(1.75%) $93.48
0.12% $ 4.07
@ $4.06
Ausgestellt: 12 Feb 2024 @ 22:00
Rendite: 0.12%
Live Chart Being Loaded With Signals
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients...
Stats | |
---|---|
Tagesvolumen | 677 694 |
Durchschnittsvolumen | 849 600 |
Marktkapitalisierung | 181.50M |
EPS | $0 ( 2024-03-14 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-05-11 |
Last Dividend | $0.250 ( 2015-09-08 ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.03 |
ATR14 | $0.0670 (1.65%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-14 | Yi Kathy | Sell | 3 250 | Restricted Stock Units |
2024-02-14 | Yi Kathy | Sell | 99 634 | Stock Option (Right to Buy) |
2024-02-14 | Stein Steven H | Sell | 3 250 | Restricted Stock Units |
2024-02-14 | Orbimed Advisors Llc | Sell | 650 600 | Common Stock |
2024-02-14 | Hayden Donald J Jr | Sell | 10 000 | Common Stock |
INSIDER POWER |
---|
-12.61 |
Last 94 transactions |
Buy: 24 821 782 | Sell: 19 785 944 |
Volumen Korrelation
Theseus Pharmaceuticals, Korrelation
10 Am meisten positiv korreliert | |
---|---|
PXLW | 0.931 |
ADXN | 0.921 |
LIAN | 0.92 |
TNXP | 0.917 |
JFIN | 0.914 |
DSKE | 0.906 |
SPRB | 0.904 |
SRRK | 0.902 |
MEUSW | 0.897 |
LX | 0.895 |
10 Am meisten negativ korreliert | |
---|---|
GRPH | -0.881 |
AHPI | -0.842 |
EA | -0.834 |
TUEM | -0.826 |
VERA | -0.818 |
MTEX | -0.814 |
LCAP | -0.812 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Theseus Pharmaceuticals, Korrelation - Währung/Rohstoff
Theseus Pharmaceuticals, Finanzdaten
Annual | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $-438 000 (0.00 %) |
EPS: | $-1.220 |
FY | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $-438 000 (0.00 %) |
EPS: | $-1.220 |
FY | 2021 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-2.84 |
FY | 2020 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-1.010 |
Financial Reports:
No articles found.
Theseus Pharmaceuticals, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.250 | 2014-08-26 |
Last Dividend | $0.250 | 2015-09-08 |
Next Dividend | $0 | N/A |
Payout Date | 2015-09-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $1.250 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.55 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.238 | 1.200 | -7.94 | -9.52 | [0 - 0.3] |
returnOnEquityTTM | -0.245 | 1.500 | -3.83 | -5.75 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 29.93 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 29.29 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.70 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0156 | -1.500 | 9.74 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 88.35 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.133 | 2.00 | -0.378 | -0.755 | [0 - 30] |
freeCashFlowPerShareTTM | -1.134 | 2.00 | -0.567 | -1.134 | [0 - 20] |
debtEquityRatioTTM | 0.0163 | -1.500 | 9.93 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -13.58 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.984 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.19 | 1.000 | -0.423 | 0 | [1 - 100] |
returnOnEquityTTM | -0.245 | 2.50 | -2.46 | -5.75 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.134 | 2.00 | -0.378 | -1.134 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.133 | 2.00 | -0.378 | -0.755 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00632 | 1.500 | -3.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.553 |
Theseus Pharmaceuticals,
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.